1. Nat. Rev. Cardiol. doi:10.1038/nrcardio.2016.209
Figure 1 Lipid levels, lipid-modifying drugs, and risk of type 2 diabetes mellitus and CHD
Figure 1 | Lipid levels, lipid-modifying drugs, and risk of type 2 diabetes mellitus and CHD. Evidence from randomized clinical trials (RCTs) and Mendelian randomization (MR) studies on the relationship between commonly measured lipid fractions — LDL cholesterol (LDL-C), triglycerides (TGs), and HDL cholesterol (HDL-C) — or lipid-modifying drug targets — 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the essential enzyme in the cholesterol-synthesis cascade and inhibited by statins7; Niemann–Pick C1-like protein 1 (NPC1L1), inhibited by ezetimibe9; and proprotein convertase subtilisin/kexin type 9 (PCSK9), the main protein involved in LDL-receptor degradation during receptor recycling10 — and risk of type 2 diabetes mellitus and coronary heart disease (CHD).
Swerdlow, D. I. & Humphries, S. E. (2017) Common and rare genetic variants and risk of CHD
Nat. Rev. Cardiol. doi: /nrcardio